There was a numerical trend towards benefit in the treatment group with a 4.2% difference in FVC percent predicted, though it did not reach statistical significance ( 18 ).
← all excerpts
Cyclophosphamide for the treatment of Acute Exacerbation of Interstitial Lung Disease: A Review of the Literature.
1
—
—